跳至主要内容
临床试验/EUCTR2007-001645-17-GB
EUCTR2007-001645-17-GB进行中(未招募)不适用

Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease

Royal Brompton and Harefield NHS Trust0 个研究点开始时间: 2007年10月10日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Patients >=18yrs, <80yrs
  • 2. Patients with Idiopathic Pulmonary Fibrosis or fibrotic Non-Specific Pneumonitis according to ATS/ERS criteria.
  • 3. Patients with mild pulmonary hypertension or at risk of developing pulmonary hypertension (Pre-PH), as defined by:
  • o Mild-PH: RHC: mean PAH 25-35mmHg, PCWP<15mmHg, and 6-minute walk test oxygen desaturation <89%
  • o Pre-PH: RHC: mean PAP <25mmHg, PCWP<15mmHg, 6-minute walk test oxygen desaturation <89%
  • 4. Patients providing written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Patients <18, >80yrs.
  • 2. Patients with unstable disease, or an acute exacerbation of their underlying fibrotic lung disease.
  • 3. Patients with significant other organ co-morbidity including hepatic or renal impairment.
  • 4. Patients with systolic BP < 85mmHg
  • 5. Patients with other conditions that may affect the ability to perform a 6-minute walk test.
  • 6. Patients unable to provide informed consent and comply with the patient protocol.
  • 7. Patients receiving excluded medications (including: epoprostenol, or prostacyclin analogues, phosphodiesterase inhibitors, other endothelin receptor antagonists, drugs with potential interaction with bosentan such as glibenclamide, fluconazole, cyclosporin A, or tacrolimus, and other invesgational agents).
  • 8. Patients with planned surgical intervention during the study period.
  • 9. Pregnant patients
  • 10. Patients with resting oxygen saturation <90%
  • 11. Patients with clinically overt ischaemic heart disease
  • 12. Patients with predominant emphysema on CT scan (in excess of interstitial changes)

研究者

发起方
Royal Brompton and Harefield NHS Trust

相似试验